Lower-Dose Cancer Drug Extends Lives in India for $230/Month

A simple question is changing cancer treatment for millions: what if patients need less medicine than we thought?

Researchers in India just proved that an ultra-low dose of nivolumab, a cancer immunotherapy that typically costs tens of thousands of dollars yearly, can significantly extend lives when combined with affordable chemotherapy pills. The entire monthly treatment costs about $230.

The study focused on head and neck squamous cell carcinoma, India's second most common cancer. Despite how widespread the disease is, less than 3% of eligible Indian patients can afford standard immunotherapy drugs. That's about to change.

Scientists at Tata Memorial Centre in Mumbai tested their ultra-low-dose approach on 422 adults with advanced disease. Half received standard platinum-based chemotherapy. The other half got the new combination, called TMC-I, pairing oral chemotherapy pills with tiny doses of nivolumab.

Patients on TMC-I lived a median of 10.3 months compared to 6.2 months with standard treatment. After one year, 46% of TMC-I patients were still alive versus just 23% in the control group. The new treatment also caused fewer severe side effects, with serious adverse events dropping by 10 percentage points.

The results were so compelling that TMC-I has already become India's preferred first-line treatment for this cancer, according to lead researcher Minit Jalan Shah.

The Ripple Effect

This discovery could reshape cancer treatment far beyond India's borders. Julie Gralow, chief medical officer at the American Society of Clinical Oncology, says there's growing momentum for a head-to-head trial comparing standard doses with low doses of immunotherapy.

If such a study includes U.S. standard-of-care treatment as a comparison, the results could prove revolutionary. America might learn from lower-resource settings how to dose these drugs more appropriately, Gralow explained at ASCO's annual meeting.

The implications for U.S. healthcare are massive. Twelve similar immunotherapy drugs currently have FDA approval, each priced at premium levels. Understanding whether lower doses work equally well could slash cancer treatment costs while maintaining the same benefits for patients.

Gralow pointed out that anything helping doctors better understand optimal dosing, identify which patients benefit most, and reduce unnecessary expenses serves both patients and the entire healthcare system.

For now, millions of Indian patients with head and neck cancer finally have access to immunotherapy that was previously financially impossible, proving that innovative thinking about dosing can be just as powerful as discovering new drugs.